291 results about "Methicillin-resistant Staphylococcus aureus" patented technology

The present invention relates to nanosilver-containing antibacterial and antifungal granules ("NAGs"). The NAGs have longlasting inhibitory effect on a broad-spectrum of bacteria and fungi, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C. The NAGs contain ground stalk marrow of the plant Juncus effusus L. which has been dispersed with nanosilver particles. The nanosilver particles are about 1-100 nm in diameter. Each of the nanosilver particles contain a metallic silver core which is surrounded by silver oxide. The present invention also provides a process for making the NAGs. The NAGs can be used in a variety of healthcare and industrial products. Examples of the healthcare products include, but are not limited to, ointments or lotions to treat skin trauma, soaking solutions or cleansing solutions for dental or women hygiene, medications for treating gastrointestinal bacteria infections, sexual related diseases, and eye diseases. Examples of industrial products include, but are not limited to, food preservatives, water disinfectants, paper disinfectants, construction filling materials (to prevent mold formation).

Environmentally-friendly, natural essential oil based foamable compositions can be used as antimicrobial substances. The foamable compositions contain thyme oil as the sole or principal antimicrobial agent. The foamable compositions are topically applied and may be used as a preventative and/or a therapeutic. The antimicrobial foamable compositions are highly efficacious against methicillin-resistant Staphylococcus aureus (MRSA).

The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.

This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.

The invention discloses a ring opening myrtle ketone analogue as well as a preparation method and application thereof to antibacterial medicines. The structure of the ring opening myrtle ketone analogue is shown in a formula (1) in the specification, wherein in the formula (1), R is H, a C1-C15 straight chain or branched chain or naphthenic base or an aromatic group. The ring opening myrtle ketone analogue has obvious activity of resisting Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Bacillus cereus, B.subtilis, B.thuringiensis or Escherichia coli, so the ring opening myrtle ketone analogue can be used for preparing bacterial infection resistant medicines and is especially applied to preventing and treating clinically common MRSA infectious diseases.

The invention discloses a high-efficiency bactericidal liquid detergent, and belongs to the field of sanitary products. The invention aims to provide a high-efficiency and safe product processed by modern biotechnology product. The high-efficiency bactericidal liquid detergent achieves the function of removing dirt of clothes, has outstanding washing ability, strong detergency and convenient use, particularly has good bactericidal and disinfectant functions and has the property of killing methicillin-resistant Staphylococcus aureus. The production of a bactericide added in the liquid detergent utilizes ferment raw materials with low cost, adopts the modern biotechnology, and has simple process and low cost. Therefore, the high-efficiency bactericidal liquid detergent has strong disinfection capacity, safety, low price and high technology content.

The invention provides a new strain FM 603 of bacillus coagulans, and the preservation number of the strain is CGMCC NO.10221. The strain can generate bacteriocin antibacterial substances and achieves antibacterial activity for Gram-positive pathogenic bacteria such as Listeria monocytogenes, staphylococcus aureus, methicillin-resistant staphylococcus aureus, clostridium perfringens and clostridium difficile. The molecular weight of bacteriocin is 4276.45 Da, the partial amino acid sequence is Ala-Gly-His-Dhb-Phe-Val-Dhb-Gly-Pro, and the bacteriocin is stable under treatment of heat, acid, and pepsase or trypsin and can be degraded easily by pronase to be inactivated. The invention further provides an FM603 fermentation product which can be used as a microbiological feed additive. Animal test results show that the fermentation product can increase the laying rate of laying hens, reduce the feed-egg ratio and improve egg quality; the feed intake and daily gain of piglets are increased, and the feed conversion ratio is reduced; the daily gain and the content of lysozyme in serum of broiler chickens are increased, and the feed conversion ratio and the death rate are reduced.

The invention relates generally to novel N-thiolated beta-lactams. More specifically, the invention relates to the use of these novel antibacterial agents in the treatment or inhibition of methicillin-resistant Staphylococcus aureus.

The invention provides a primer and a probe for detecting drug resistance genes mecA in methicillin-resistant staphylococcus aureus (MRSA). The invention also provides a method and a detection kit for detecting drug resistance genes mecA in MRSA. According to the invention, the conserved sequence part of drug resistance genes mecA is directly detected without being affected by the mecA gene variation of strains, and a result is a gold standard of MRSA diagnosis. The specific primer and the probe provided by the invention are applicable to currently known strains containing sequence variation.

The invention provides an antibiotic controlled freed porous bone replacing material and a preparation method thereof. The antibiotic controlled freed porous bone replacing material is characterized by consisting of polycaprolactone, nano tricalcium phosphate, chitosan/vancomycin microsphere with sodium alginate coating, and tobramycin. The preparation method comprises the following steps: dissolving the chitosan in glacial acetic acid solution, dissolving the vancomycin in the glacial acetic acid solution, spraying and drying to prepare the chitosan/vancomycin microsphere; moving the microsphere into the sodium alginate solution; dissolving the microsphere and the nano tricalcium phosphate powder in dichloromethane solution of the polycaprolactone, adding a pore-forming agent, stirring uniformly, extruding and forming, putting the formed material in deionized water after the dichloromethane is volatilized, dissolving out the pore-forming agent, and obtaining the porous material; and immersing the porous material into tobramycin sulfate solution, and drying. The invention has the advantages that the vancomycin and the tobramycin can be released simultaneously in the early stage. The two antibiotics can kill the intractable bacteria of methicillin-resistant Staphylococcus aureus and the like, which are common clinically and infected chronically by bones.

The invention provides a marine Streptomyces strain and use thereof. The strain provided by the invention is Streptomyces sp. FXJ7.388, and the collection number of the strain is CGMCC No.4474. The invention also provides the use of the strain in the preparation of an antibacterial product. The antibacterial effect is to inhibit gram-positive bacteria, including Multi-resistant Staphylococcus aureus (MRSA 1-1), staphylococcus aureus CGMCC1.2386, bacillus subtilisGCMCC1.2428 and/or Candida albicans 2.538. Experiments prove that the Streptomyces sp. FXJ7.388 separated by the invention has the advantage of resisting gram-positive bacteria and Candida albicans, namely having high activity for resisting MRSA, staphylococcus aureus AND bacillus subtilis and certain inhibiting effect on Candida albicans.

Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment, prevention and prophylaxis of Staphylococcus aureus infections in a subject.

The present invention provides improved tests for the detection of methicillin-resistant Staphylococcus aureus. The tests are particularly useful for eliminating false positive results due to the presence of a mixed bacterial population in patient samples.

The invention belongs to the field of novel medicines and compounds, and discloses a thiazole orange styrene derivative, a method for preparing the same and application of the thiazole orange styrene derivative to preparing medicines capable of resisting medicine-resistant bacteria. The thiazole orange styrene derivative is of a structure shown as a formula (I). An R in the formula is defined as an instruction book. The method includes carrying out condensation reaction on thiazole orange analogues and different types of aromatic aldehyde to obtain the thiazole orange styrene derivative. The thiazole orange styrene derivative, the method and the application have the advantages that the method is simple, and raw materials for the thiazole orange styrene derivative are easily available; excellent interaction between the thiazole orange styrene derivative and bacterium division proteins FtsZ can be realized, and accordingly reproduction of diversified medicine-resistant bacteria such as vancomycin-resistant enterococci and methicillin-resistant staphylococcus aureus can be inhibited; the thiazole orange styrene derivative is little in toxic and side effect and has a prospect of being developed to obtain novel antibiotic medicines.

The invention discloses supramolecular hydrogel and also discloses a preparation method and application of the supramolecular hydrogel. The supramolecular hydrogel disclosed by the invention is prepared from a 2-deoxy-2-fluoro-guanosine analogue and silver ions. The silver-ion supramolecular antibacterial hydrogel provided by the invention has the advantages of simplicity in preparation, low toxicity, good biocompatibility, excellent stable performance and the like; the silver ions can be effectively alleviated and the antibacterial activity is good; especially, the silver-ion supramolecular antibacterial hydrogel has relatively high antibacterial activity on methicillin-resistant staphylococcus aureus ATCC25923 and ATCC33591, and fusobacterium nucleatum; the silver-ion supramolecular antibacterial hydrogel is prepared into an antibacterial material and has a relatively good application prospect.

The invention discloses methicillin-resistant staphylococcus aureus (MRSA) recombinant multivalent subunit genetic engineering vaccine and a method for preparing the same. The recombinant multivalent subunit genetic engineering vaccine is prepared by recombining, fussing and expressing the active and functional fragments of two antigen molecules of ClfA and IsdB and the specific enterotoxin C mutant for the MRSA to construct recombinant multivalent genetic engineering antigen protein under the assistance of aluminum adjuvant. The recombinant multivalent subunit genetic engineering vaccine is constructed with a unique method and prepared with simple process, is easy to be amplified and has good repeatability and high protein purity. The experiment on the animal shows that the recombinant multivalent subunit genetic engineering vaccine can effectively stimulate the body to produce higher humoral immune response and have good immune protection function.

The invention discloses an application of a macrolide compound or a salt thereof and a pharmaceutical composition containing the macrolide compound or the salt, and provides a pharmaceutical composition. The pharmaceutical composition comprises one or more of a macrolide compound as shown in a formula 1 in the specification, a macrolide compound as shown in a formula 1' in the specification and pharmaceutically acceptable salts thereof, and beta-lactam antibiotics. One or more of the macrolide compound as shown in the formula 1, the macrolide compound as shown in the formula 1' and pharmaceutically acceptable salts thereof disclosed by the invention has/have the effects of improving the effects of beta-lactam antibiotics and inhibiting methicillin-resistant staphylococcus aureus (MRSA); the macrolide compound is a novel synergist, is good in in-vitro synergism, is capable of relieving the drug resistance of the methicillin-resistant staphylococcus aureus (MRSA) on beta-lactam antibiotics, and is a medicine with good market development prospect.

The invention discloses an antibody against staphylococcal enterotoxin B and application thereof. The heavy chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 5, SEQ ID No. 6 and SEQ ID No. 7, or is composed of CDR variants with equivalent functions; and light chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 9, SEQ ID No. 10 and SEQ ID No. 11, or is composed of CDR variants with equivalent functions. The antibody against staphylococcal enterotoxin B is capable of specifically binding with staphylococcal enterotoxin B or free enterotoxin B; and thus, the antibody can be used fortreating, preventing and diagnosing staphylococcus aureus infection. Therefore, the antibody against staphylococcal enterotoxin B will be an important research direction in the fields of "non-antibiotic" treatment of methicillin-resistant staphylococcus aureus infection and drug resistance development control.